CoChat
Sign Up
Cited by 103HIV Research and TreatmentSARS-CoV-2 and COVID-19 ResearchImmunotherapy and Immune Responses

The DOI matches its Crossref record; 57 of the 59 references it cites were found in a registry or an index.

Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques

Open access
Pardi, Norbert, LaBranche, Celia C., Ferrari, Guido, Cain, Derek W., Tombácz, István, Parks, Robert J., Muramatsu, Hiromi, Mui, Barbara L., Tam, Ying K., Karikó, Katalin, Polacino, Patricia, Barbosa, Christopher J., Madden, Thomas D., Hope, Michael J., Haynes, Barton F., Montefiori, David C., Hu, Shiu-Lok, Weissman, Drew·2019·Molecular Therapy - Nucleic Acids
DOI 10.1016/j.omtn.2019.03.003PMC PMC6454128
Open this paper in CoChat — free account

Abstract

Despite the enormous effort in the development of effective vaccines against HIV-1, no vaccine candidate has elicited broadly neutralizing antibodies in humans. Thus, generation of more effective anti-HIV vaccines is critically needed. Here we characterize the immune responses induced by nucleoside-modified and purified mRNA-lipid nanoparticle (mRNA-LNP) vaccines encoding the clade C transmitted/founder HIV-1 envelope (Env) 1086C. Intradermal vaccination with nucleoside-modified 1086C Env mRNA-LNPs elicited high levels of gp120-specific antibodies in rabbits and rhesus macaques. Antibodies generated in rabbits neutralized a tier 1 virus, but no tier 2 neutralization activity could be measured. Importantly, three of six non-human primates developed antibodies that neutralized the autologous tier 2 strain. Despite stable anti-gp120 immunoglobulin G (IgG) levels, tier 2 neutralization titers started to drop 4 weeks after booster immunizations. Serum from both immunized rabbits and non-human primates demonstrated antibody-dependent cellular cytotoxicity activity. Collectively, these results are supportive of continued development of nucleoside-modified and purified mRNA-LNP vaccines for HIV. Optimization of Env immunogens and vaccination protocols are needed to increase antibody neutralization breadth and durability.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omtn.2019.03.003

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Antibody Responses after Nucleoside-Modified 1086C Env mRNA-LNP Immunization in Rabbits (A) Schematic of experimental design. Rabbits were immunized intradermally with 50 μg HIV-1 1086C B2 ecto Env or influenza virus A/California/07/2009 HA-encoding nucleoside-modified mRNA-LNPs or poly(C) RNA-LNPs at weeks 0, 6, 18, and 30. (B) Sera were collected at weeks 0, 6, 18, 30, 34, and 38, and the kinetics of 1086C anti-gp120 IgG titers were determined by endpoint dilution ELISA. Vertical black arrows indicate dates of immunizations. Shaded area indicates the limit of detection. n = 5 rabbits and each symbol represents one animal. (C) Neutralization titers (expressed as the reciprocal serum dilution resulting in 50% inhibition of infection) from sera were determined against the MW965.26 (tier 1A) virus. Each symbol represents one animal. Means of values with SEM are displayed. Statistical significance of differences (denoted by asterisks) was determined using two-way ANOVA with Bonferroni multiple comparisons after log transformation of values; p < 0.0001. ** denotes significant difference to *p < 0.005.
Figure 1 Antibody Responses after Nucleoside-Modified 1086C Env mRNA-LNP Immunization in Rabbits (A) Schematic of experimental design. Rabbits were immunized intradermally with 50 μg HIV-1 1086C B2 ecto Env or influenza virus A/California/07/2009 HA-encoding nucleoside-modified mRNA-LNPs or poly(C) RNA-LNPs at weeks 0, 6, 18, and 30. (B) Sera were collected at weeks 0, 6, 18, 30, 34, and 38, and the kinetics of 1086C anti-gp120 IgG titers were determined by endpoint dilution ELISA. Vertical black arrows indicate dates of immunizations. Shaded area indicates the limit of detection. n = 5 rabbits and each symbol represents one animal. (C) Neutralization titers (expressed as the reciprocal serum dilution resulting in 50% inhibition of infection) from sera were determined against the MW965.26 (tier 1A) virus. Each symbol represents one animal. Means of values with SEM are displayed. Statistical significance of differences (denoted by asterisks) was determined using two-way ANOVA with Bonferroni multiple comparisons after log transformation of values; p < 0.0001. ** denotes significant difference to *p < 0.005.CC BY · PubMed Central
Figure 2 Neutralizing Antibody Titers in Rabbits Neutralizing antibodies generated by 1086C B2 ecto Env mRNA-LNP immunizations in rabbits were measured in week 0, 18, and 34 sera by the TZM-bl assay against HIV-1 isolates MW965.26 (tier 1A), Ce1086_B2 (autologous tier 2), and Ce1176_A3 (tier 2). Data are reported as dilution of sera required to inhibit 50% of viral infectivity (ID50) and labeled in blue (21–100), yellow (101–1,000), orange (1,001–5,000), and red (>5,001).
Figure 2 Neutralizing Antibody Titers in Rabbits Neutralizing antibodies generated by 1086C B2 ecto Env mRNA-LNP immunizations in rabbits were measured in week 0, 18, and 34 sera by the TZM-bl assay against HIV-1 isolates MW965.26 (tier 1A), Ce1086_B2 (autologous tier 2), and Ce1176_A3 (tier 2). Data are reported as dilution of sera required to inhibit 50% of viral infectivity (ID50) and labeled in blue (21–100), yellow (101–1,000), orange (1,001–5,000), and red (>5,001).CC BY · PubMed Central
Figure 3 ADCC Activity after Nucleoside-Modified 1086C Env mRNA-LNP Immunization in Rabbits ADCC activity in rabbit sera obtained at weeks 0, 18, and 34 was assessed. (A and B) ADCC responses against the 1086C recombinant gp120-coated target cells (GTL assay). Granzyme B activity (A) and ADCC antibody titers (B) were determined. The cut-off for positivity (indicated with a horizontal dotted line) was ≥8% of granzyme B activity after subtracting the background measured in the uncoated cells. Antibody titers are expressed as the dilution at which the dilution curve interpolate with the 15% cut-off value. Each symbol represents one animal. (C and D) ADCC responses against HIV-infected cells (luciferase-based assay). Specific killing activity (C) and ADCC antibody titers (D) were determined. The analysis of the results was conducted after subtracting the background detected with the pre-immunization (week 0) samples. The horizontal dotted line indicates the cut-off for positivity. n = 5 rabbits and each symbol represents one animal. Means of values with SEM are displayed. Statistical significance of differences (denoted by asterisks) was determined using two-way ANOVA with Bonferroni multiple comparisons after log transformation of values; p < 0.0001. ** denotes significant difference to *p < 0.005.
Figure 3 ADCC Activity after Nucleoside-Modified 1086C Env mRNA-LNP Immunization in Rabbits ADCC activity in rabbit sera obtained at weeks 0, 18, and 34 was assessed. (A and B) ADCC responses against the 1086C recombinant gp120-coated target cells (GTL assay). Granzyme B activity (A) and ADCC antibody titers (B) were determined. The cut-off for positivity (indicated with a horizontal dotted line) was ≥8% of granzyme B activity after subtracting the background measured in the uncoated cells. Antibody titers are expressed as the dilution at which the dilution curve interpolate with the 15% cut-off value. Each symbol represents one animal. (C and D) ADCC responses against HIV-infected cells (luciferase-based assay). Specific killing activity (C) and ADCC antibody titers (D) were determined. The analysis of the results was conducted after subtracting the background detected with the pre-immunization (week 0) samples. The horizontal dotted line indicates the cut-off for positivity. n = 5 rabbits and each symbol represents one animal. Means of values with SEM are displayed. Statistical significance of differences (denoted by asterisks) was determined using two-way ANOVA with Bonferroni multiple comparisons after log transformation of values; p < 0.0001. ** denotes significant difference to *p < 0.005.CC BY · PubMed Central
Figure 4 Antibody Responses after Nucleoside-Modified 1086C Env mRNA-LNP Immunization in Rhesus Macaques (A) Schematic of experimental design. Rhesus macaques were immunized intradermally with 50 μg HIV-1 1086C.DRss Env mRNA-LNPs at weeks 0, 4, 20, 32, and 48. (B) Sera were collected at weeks 0, 4, 8, 24, 34, 40, 50, and 52, and the kinetics of 1086C anti-gp120 IgG titers were determined by endpoint dilution ELISA. Vertical black arrows indicate dates of immunizations. Shaded area indicates the limit of detection. Each symbol represents one animal. (C–E) Neutralization titers (expressed as the reciprocal serum dilution resulting in 50% inhibition of infection) from sera were determined against MW965.26 (C, tier 1A), 92BR025.9 (D, tier 1B), and Ce1086_B2 (E, autologous tier 2). n = 6 monkeys and each symbol represents one animal. Means of values with SEM are displayed. Statistical significance of differences (denoted by asterisk) was determined using one-way ANOVA with Bonferroni multiple comparisons to week 0 samples after log transformation of values; p < 0.0001.
Figure 4 Antibody Responses after Nucleoside-Modified 1086C Env mRNA-LNP Immunization in Rhesus Macaques (A) Schematic of experimental design. Rhesus macaques were immunized intradermally with 50 μg HIV-1 1086C.DRss Env mRNA-LNPs at weeks 0, 4, 20, 32, and 48. (B) Sera were collected at weeks 0, 4, 8, 24, 34, 40, 50, and 52, and the kinetics of 1086C anti-gp120 IgG titers were determined by endpoint dilution ELISA. Vertical black arrows indicate dates of immunizations. Shaded area indicates the limit of detection. Each symbol represents one animal. (C–E) Neutralization titers (expressed as the reciprocal serum dilution resulting in 50% inhibition of infection) from sera were determined against MW965.26 (C, tier 1A), 92BR025.9 (D, tier 1B), and Ce1086_B2 (E, autologous tier 2). n = 6 monkeys and each symbol represents one animal. Means of values with SEM are displayed. Statistical significance of differences (denoted by asterisk) was determined using one-way ANOVA with Bonferroni multiple comparisons to week 0 samples after log transformation of values; p < 0.0001.CC BY · PubMed Central
Figure 5 Neutralizing Antibody Titers in Rhesus Macaques Neutralizing antibodies generated by 1086C.DRss Env mRNA-LNP immunizations in rhesus macaques were measured in week 0, 8, 24, 34, 40, 50, and 52 sera by the TZM-bl assay against HIV-1 isolates MW965.26 (tier 1A), 92BR025.9 (tier 1B), Ce1086_B2 (autologous tier 2), 25710-2.43 (tier 2), and Ce1176_A3 (tier 2). Data are reported as dilution of sera required to inhibit 50% of viral infectivity (ID50) and labeled in blue (21–100), yellow (101–1,000), orange (1,001–5,000), and red (>5,001).
Figure 5 Neutralizing Antibody Titers in Rhesus Macaques Neutralizing antibodies generated by 1086C.DRss Env mRNA-LNP immunizations in rhesus macaques were measured in week 0, 8, 24, 34, 40, 50, and 52 sera by the TZM-bl assay against HIV-1 isolates MW965.26 (tier 1A), 92BR025.9 (tier 1B), Ce1086_B2 (autologous tier 2), 25710-2.43 (tier 2), and Ce1176_A3 (tier 2). Data are reported as dilution of sera required to inhibit 50% of viral infectivity (ID50) and labeled in blue (21–100), yellow (101–1,000), orange (1,001–5,000), and red (>5,001).CC BY · PubMed Central
Figure 6 Neutralizing Antibody Epitope Mapping in Rhesus Monkey A16334 Epitope-mapping experiments were performed with week 34 serum from rhesus macaque A16334 using pseudoviruses with resistance mutations for known bnAbs targeting various regions of the HIV-1 envelope. Concentration (μg/mL) of bnAbs required to inhibit 50% of viral infectivity (IC50) is shown. Serum neutralization titers are reported as dilution of serum required to inhibit 50% of viral infectivity (ID50). *Positive deflection (44%) was detected for Ce1086_B2.N611A.
Figure 6 Neutralizing Antibody Epitope Mapping in Rhesus Monkey A16334 Epitope-mapping experiments were performed with week 34 serum from rhesus macaque A16334 using pseudoviruses with resistance mutations for known bnAbs targeting various regions of the HIV-1 envelope. Concentration (μg/mL) of bnAbs required to inhibit 50% of viral infectivity (IC50) is shown. Serum neutralization titers are reported as dilution of serum required to inhibit 50% of viral infectivity (ID50). *Positive deflection (44%) was detected for Ce1086_B2.N611A.CC BY · PubMed Central
Figure 7 ADCC Activity after Nucleoside-Modified 1086C Env mRNA-LNP Immunization in Rhesus Macaques ADCC activity in monkey sera obtained at weeks 0 and 34 was assessed. (A and B) ADCC responses against HIV-1 TV-1 and 1086C recombinant gp120-coated target cells (GTL assay). Granzyme B activity (A) and ADCC antibody titers (B) were determined. The cut-off for positivity (indicated with a horizontal dotted line) was ≥8% of granzyme B activity after subtracting the background measured in the uncoated cells. Antibody titers are expressed as the dilution at which the dilution curve interpolate with the 15% cut-off value. n = 6 monkeys and each symbol represents one animal. Means of values with SEM are displayed. Statistical significance of differences (denoted by asterisk) was determined using two-way ANOVA with Bonferroni multiple comparisons (after log transformation of values in the case of B); p < 0.01.
Figure 7 ADCC Activity after Nucleoside-Modified 1086C Env mRNA-LNP Immunization in Rhesus Macaques ADCC activity in monkey sera obtained at weeks 0 and 34 was assessed. (A and B) ADCC responses against HIV-1 TV-1 and 1086C recombinant gp120-coated target cells (GTL assay). Granzyme B activity (A) and ADCC antibody titers (B) were determined. The cut-off for positivity (indicated with a horizontal dotted line) was ≥8% of granzyme B activity after subtracting the background measured in the uncoated cells. Antibody titers are expressed as the dilution at which the dilution curve interpolate with the 15% cut-off value. n = 6 monkeys and each symbol represents one animal. Means of values with SEM are displayed. Statistical significance of differences (denoted by asterisk) was determined using two-way ANOVA with Bonferroni multiple comparisons (after log transformation of values in the case of B); p < 0.01.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

Sorted by citations

Items 101–103 of 103

Related

See all

Metadata

Authors
Pardi, N., LaBranche, C. C., Ferrari, G., Cain, D. W., Tombácz, I., Parks, R. J., Muramatsu, H., Mui, B. L., Tam, Y. K., Karikó, K., Polacino, P., Barbosa, C. J., Madden, T. D., Hope, M. J., Haynes, B. F., Montefiori, D. C., Hu, S.-L., & Weissman, D.
Affiliations
  • University of Pennsylvania (US)
  • Duke Medical Center (US)
  • Duke University (US)
  • Acuitas Therapeutics (Canada) (CA)
  • BioNTech (Germany) (DE)
  • University of Washington (US)
Corresponding author
  • Pardi, Norbert
  • Weissman, Drew
ORCID
Venue
Molecular Therapy - Nucleic Acids
Publisher
Elsevier BV
Published
2019-04
Volume
15
Pages
36-47
ISSN
2162-2531 (ISSN-L)
DOI
10.1016/j.omtn.2019.03.003
PMC
PMC6454128
OpenAlex
W2924788224
Cited by
103
References
59
Citations by year
2026: 4 · 2025: 11 · 2024: 13 · 2023: 16 · 2022: 17 · 2021: 26 · 2020: 14 · 2019: 2
FWCI
8.26
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Therapy — Nucleic Acids (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institute of Allergy and Infectious Diseases (UM1 AI100645, HHSN272201100016C)
  • Bill and Melinda Gates Foundation
  • National Institutes of Health (P51 OD010425)
Topics
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
HIV-1 vaccine, nucleoside-modified mRNA, mRNA-LNP vaccine, HIV-1 envelope glycoprotein, neutralizing antibodies, antibody-dependent cellular cytotoxicity, intradermal vaccination, booster vaccination, antibody persistence, rabbits, rhesus monkeys

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review